DALLAS, Oct. 11, 2017 -- Dougherty’s Pharmacy, Inc. (OTCQB:MYDP) (the “Company”) today announced that Andrew Komuves, President of Pharmacy Operations, has resigned effective October 5, 2017. In conjunction with Mr. Komuves’ departure, the Company is realigning its pharmacy operations, which have always reported to Mark Heil, President and CFO of Dougherty’s Pharmacy, Inc.
“We appreciate Andy’s five years of service to Dougherty’s and wish him well in all his future endeavors,” said James C. Leslie, the Company’s Chairman of the Board.
“We anticipate a seamless transition of the operations oversight as we will reassign Andy’s various responsibilities to several capable people within the organization,” Leslie said. “Our focus continues to be on the strategic growth and financial enhancement of Dougherty’s. We are stepping up our sales and marketing efforts throughout the organization and are working to build our brand recognition within the market. We believe these operational and marketing initiatives will strengthen our business and lead to enhanced long-term value for our shareholders.”
About Dougherty’s Pharmacy, Inc.
Dougherty’s Pharmacy, Inc. is a retail pharmacy chain focused on successfully acquiring, managing and growing community-based pharmacies in the Southwest Region of the United States. On June 9, 2017, the Company changed its name from Ascendant Solutions, Inc. to Dougherty’s Pharmacy, Inc. to better reflect the corporate vision and operating structure. Dougherty’s currently has approximately $48 million in net operating loss carryforwards which can be used to shelter future income, thus enhancing free cash flow or debt service capabilities. Interested investors can access financials and stock trading information for Dougherty’s at OTCMarkets.com or at www.doughertys.com.
| Contacts: | ||||
| Mark S. Heil | Geralyn DeBusk or Tom Carey | |||
| President and CFO | Halliburton Investor Relations | |||
| 972-250-0945 | 972-458-8000 |


Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 



